The epidermal growth factor receptor (EGFR) is overexpressed and activated in many human cancers and predicts poor patient prognosis. Targeting the kinase domain with specific EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib has been used in anticancer treatments. However, patient response rates in different human cancers were initially low. Only a subgroup of nonsmall-cell lung cancer (NSCLC) patients harboring EGFR-activating mutations responds to EGFR TKI treatment, but most of these responders relapse and acquire resistance. Recent clinical studies have demonstrated that MET proto-oncogene overexpression correlates with resistance to EGFR TKI treatment. Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. However, only little is known about the HGF/Met-induced EGFR TKI resistance mechanism in other human cancer types. Therefore, in order to develop possible new anticancer strategies for diverse human cancers, we screened 12 carcinoma cell lines originating from the breast, kidney, liver and tongue for HGF-induced EGFR tyrosine kinase (TK)-inhibition. In addition, in order to advance our understanding of a TK-inactive EGFR, we used EGFR co-immunoprecipitation, followed by mass spectrometry to identify novel HGF-induced EGFR binding partners, which are potentially involved in tyrosine kinase-independent EGFR signaling mechanisms. Here we show for the first time that HGF-induced EGFR TK-inhibition is a very common mechanism in human cancers, and that the kinase-inactive EGFR directly interacts with and stabilizes several cancer-relevant proteins, including the receptor tyrosine kinases Axl and EphA2, and the CUB domain-containing protein-1. This study has strong implications for the development of new anticancer strategies.
INTRODUCTION
The epidermal growth factor receptor (EGFR) has a fundamental role in cancer progression and has therefore been among the most promising targets in the development of anticancer strategies. [1] [2] [3] [4] [5] [6] In normal cells, EGFR signaling is tightly controlled; however, in tumor cells, overexpression of EGFR, activating mutations within its kinase domain and aberrant expression of EGFR ligands result in EGFR hyperactivation. Increased levels of EGFR gene expression are found in many human carcinomas and correlate with poor prognosis. 1, [7] [8] [9] The cognate EGFR ligands, including amphiregulin (AR), EGF and TGFa are produced either by the tumor cells themselves or by cells of the tumor microenvironment. 7, 10, 11 EGFR activation upon ligand binding to the extracellular domain is followed by dimerization and autophosphorylation 12, 13 and triggers pathways, which are involved in proliferation, migration and survival via phosphatidylinositol 3-kinase (PI3K)-Akt, mitogen-activated protein kinase (MAPK), as well as the signal transducer and activator of transcription 3 and 5 (STAT3/5). 5, 10, [14] [15] [16] There are two main strategies for targeted anti-EGFR treatment. The first strategy is the use of anti-EGFR monoclonal antibodies such as cetuximab and panitumumab, which bind to the extracellular domain of the receptor, thereby preventing EGFR ligands from interacting and activating the receptor. The second anti-EGFR strategy comprises EGFR tyrosine kinase inhibitors (TKI), such as gefitinib and erlotinib. TKIs are competitive adenosine triphosphate analogs, which prevent the binding of adenosine triphosphate to the intracellular tyrosine kinase (TK) domain of EGFR, thereby blocking TK activity and signal transduction. Anti-EGFR monoclonal antibodies are approved for the treatment of carcinomas of the head and neck, non-small-cell lung cancer (NSCLC) and for colon cancer, and EGFR TKIs have been approved for the treatment of NSCLC and pancreatic carcinomas. 17 However, inhibition of EGFR has yielded only modest clinical outcomes: [18] [19] [20] [21] therapy responses upon EGFR TKI treatment are only observed in a small subgroup of NSCLC patients, harboring EGFR-activating mutations 22 or gene amplification, but most of these patients eventually develop resistance. [23] [24] [25] [26] Several clinical studies have revealed a strong correlation between resistance to EGFR TKI and MET amplification and activation. 24, [27] [28] [29] [30] [31] [32] MET, a proto-oncogene encoding the receptor for hepatocyte growth factor (HGF) and a strong inducer of cell invasion and metastasis, 33 is coexpressed with EGFR in many human cancers. [34] [35] [36] Engelman et al. 24 reported that MET amplification causes gefitinib resistance in lung cancer cell lines by circumventing the blocked EGFR activity via a HER3-dependent activation of the PI3K-Akt pathway. Similarly, Wheeler et al. 37 showed that acquired resistance to the anti-EGFR monoclonal antibody cetuximab is accompanied by upregulation and activation of HER3 and Met. In addition, it was shown that stromal fibroblasts can acquire oncogenic properties. 38 A recent study in NSCLC cell lines harboring EGFR-activating mutations suggested HGF, which is mainly produced by fibroblasts of the tumor stroma, induces short-term resistance to EGFR TKIs. 31 Strikingly, EGFR expression levels in human cancers correlate with disease progression, but not with responsiveness to EGFR TKI treatment, 39 implicating that EGFR may contribute to the tumor progression in a kinase-independent manner. This raises the question whether HGF-mediated kinase inhibitor-insensitive EGFR can still signal via alternative pathways. Therefore, we characterized HGF/EGFR cooperation in a set of different cancer cell lines to receive new insights into the expanding field of microenvironment-induced processes affecting tumor progression and resistance mechanisms.
Here, we investigated HGF/EGFR cooperation and found completely blocked EGFR TK activity upon HGF treatment in all the tested cancer tissues. However, upon HGF treatment, EGFR strongly interacts with various proteins, known to be markers for a highly metastatic phenotype-notably, these interactions are not affected by EGFR TKI treatment.
RESULTS

HGF is a paracrine inhibitor of classical EGFR activation in epithelial cancer cells
In this study, we demonstrate that the EGFR ligand AR is transcriptionally upregulated and released into the cell culture medium of breast, liver and squamous cell carcinoma cell lines during 24 h HGF treatment (Figures 1a and b) . Previous work has documented that HGF can induce transcription-dependent upregulation of EGFR ligands in human glioma and corneal limbal epithelial cells. 40, 41 In order to investigate whether AR, out of the different members of the EGFR ligand family is the mainly released EGFR ligand, the conditioned medium of HGF-treated SCC9 cells was incubated with a neutralizing anti-AR antibody before it was used to stimulate untreated SCC9 cells. The conditioned medium of the HGF-treated cells induced strong EGFR Y1173 phosphorylation, a major autophosphorylation site of the EGFR. This phosphorylation was completely blocked by the addition of a neutralizing anti-AR antibody (Figure 1c) . However, when we analyzed EGFR phosphorylation of HGF-treated cells themselves, we found that the EGFR got activated neither on Y1173 nor on Y845, a site implicated in maintaining an active enzyme and providing a docking site for intracellular signaling proteins, 42 or Y1045, the Cbl binding site governing receptor degradation, 43 although stimulation with recombinant AR leads to a strong activation of all three phosphorylation sites (Figure 1d ). Most surprisingly, in HGF-treated cells, these phosphorylation sites remained unaffected even after stimulation with recombinant AR. Strong Met phosphorylation was still detectable 24 h after HGF treatment, although total Met levels were dramatically reduced. As amphiregulin is only one out of several EGFR-activating ligands, we aimed to investigate if inhibition of EGFR phosphorylation was also found upon stimulation with other EGFR ligands like EGF, HB-EGF and TGFa. The EGFR phosphorylation remained blocked, regardless of the EGFR ligand type that was used to induce phosphorylation ( Figure 1e ). To investigate whether this HGF-blocked EGFR TK activity represents a common characteristic of the epithelial cancer cells, we selected 12 human carcinoma cell lines originating from breast, kidney, liver and tongue-tissues which were found to express functional Met, as well as EGFR in primary tumors. In all tested cell lines, we observed HGF mediated the inhibition of EGFR activation after AR stimulation (Figure 2a ). To further assess the impact of the loss of EGFR TK activity on downstream signaling events, we investigated the phosphorylation of EGFR co-immunoprecipitated EGFR interactors. We found a complete inhibition of EGFR signal transducer activity upon ligand stimulation (Figure 2b ). Loss of EGFR TK activity is independent of an autocrine EGFR feedback loop Protein internalization and degradation is a common negativefeedback mechanism to attenuate growth factor receptor signaling. In order to determine whether the HGF-induced release of active AR into the cell culture medium leads to an EGFR negativefeedback loop, we analyzed total EGFR protein, as well as cell surface EGFR via western blot and FACS analyses, respectively. Interestingly, we neither observed changes in total EGFR protein amount (Figure 2a , EGFR immunoblot) nor did we detect significant differences in cell surface EGFR levels ( Figure 2c ). To further verify these findings, we blocked shedding of the EGFR ligands from the cell membrane by treatment of SCC9 cells with the metalloproteinase inhibitor batimastat (BB94) or DMSO during the entire period of HGF treatment ( Figure 2d , right part) before the cells were stimulated with AR ( Figure 2d ). We confirmed that the observed inhibition of EGFR TK activity is independent of the HGF-induced release of endogenous EGFR ligands.
Inhibition of EGFR TK requires ERK activation
To investigate which signal transducers downstream of HGF mediate the nonresponsiveness to the EGFR ligand stimulation, we cultured SCC9 cells and the two kidney cell lines A498 and caki-2 in the presence of MEK inhibitors (UO126 and PD98059) and a PI3 kinase inhibitor (wortmannin). The effects of these inhibitors on AR-induced EGFR activation was examined after 24 h HGF treatment. SCC9 cells were additionally treated with an inhibitor against the HGF receptor Met (AMG-458 derivate 1). Inhibitor specificity and efficacy of Met, MEK and PI3K inhibitors was analyzed 3 min after HGF treatment and is shown in Supplementary Figure S1 .
Notably, full recovery of EGFR responsiveness was achieved in all of the three tested cell lines with both MEK inhibitors, whereas the PI3 kinase inhibitor showed no effect ( Figure 2e ). In addition, the Met inhibitor AMG-458 successfully rescued the EGFR responsiveness, proofing an involvement of Met TK activity. Two different MEK inhibitors showing the same effect, argues for specific involvement of MEK rather than off-target effects of these inhibitors. This experiment reveals a MAPK pathway underlying the EGFR suppression.
HGF leads to impaired EGFR-mediated migration Next, we asked whether the HGF-mediated inhibition of EGFR TK activity has a functional consequence on the migratory behavior of SCC9 cells. In line with the widely accepted effect of HGF on cell scattering, epithelial-sheet dissociation could be detected after 24 h of HGF treatment (Figure 3a) . Owing to the fact that HGF-treated cells scatter and are in a scatter-like morphology already, it would be expected that they migrate faster toward chemoattractants compared with the cells, which are in a resting mode. Surprisingly, directed migration toward the EGFR ligand TGFa was found to be 3.3-fold reduced in HGF pretreated SCC9 cells compared with untreated cells (5.2-and 16.8-fold, respectively (Figure 3b) ). Thus, HGF stimulation of SCC9 cells results in enhanced scattering but impaired EGFR-mediated migration.
HGF induces various EGFR interactions
The finding that classical EGFR signaling is abrogated after HGF treatment although the EGFR cell surface expression level is unchanged prompted us to search for an alternative mode of EGFR action or modification. In order to identify potential HGFinduced EGFR binding partners, we subjected total lysate from SCC9 cells treated with or without HGF to EGFR co-IP, followed by mass spectrometric (MS) analysis of the captured proteins. We therefore metabolically SILAC-labeled SCC9 cells with either normal arginine and lysine (Arg0 and Lys0) or with combinations of isotopic variants of the two amino acids (Arg6 and Lys4, or Arg10 and Lys8). To distinguish between specific EGFR binders and non-specific binders, SCC9 total lysate was subjected to control beads (no antibody). In addition, we stimulated HGFtreated and untreated cells with AR, as possible EGFR interaction partners should also be present in this originally used setting of Figure 1d . Precipitated proteins were resolved by SDS-PAGE. Coomassie staining of the gel revealed protein bands, which were excised from the gel and digested with trypsin, followed by subsequent MS analysis (Figures 4a-c) . Figure 4d provides an overview of all HGF reduced (rp0.67; left side of left dashed line) and induced (rX1.5; right side of right dashed line) EGFR binding partners. EGFR interactors specifically induced by HGF were further selected using the following criteria: first, to discriminate EGFR binders from background binders, average ratios of the two biological replicates of EGFR-retained peptides should be at least twofold enriched compared with control beads (no antibody), indicated by cuts of rp0.5 for Arg6/Lys4 versus Arg0/Lys0 (pool A) and rX2 for Arg0/Lys0 (pool B) versus Arg6/Lys4 (pool A); second, HGF-induced EGFR binders should be 1.5-fold enriched compared with cells without HGF treatment with (Arg10/Lys8 To validate our MS data, we performed EGFR co-IP followed by western blot analysis. SCC9 cells were treated with HGF for 24 h and total cell lysate was subjected to EGFR co-IP. Immunoblots of the trapped proteins showed Axl, CUB domain-containing protein-1 (CDCP1), EphA2, integrin beta-4 and JAK1 as specifically HGFinduced EGFR interaction partners (Figure 5a, left part) . In addition, we found increased levels of Axl, CDCP1, EphA2 and integrin beta-4 in total protein lysates subjected to western blot analysis (Figure 5a, right part) , suggesting HGF-induced stabilization or upregulation. To examine whether the same changes in protein levels occur in the cell lines, which we tested for a loss of EGFR TK activity in Figure 2a (plus the colon cell line HT29), cells were treated with or without HGF for 24 h and subjected to western blot analysis. Changes in protein expression between control treatment and HGF treatment were then densitometrically measured and represented as a heat map (Figure 5b ). An upregulation of at least two interaction partners was found in seven out of ten cell lines.
HGF leads to enhanced survival upon gefitinib treatment Considering that HGF blocks EGFR TK activity, we wondered if gefitinib, an inhibitor of the EGFR TK function, can still induce apoptosis. We subjected SCC9 cells to different concentrations of gefitinib in the presence or absence of HGF and measured cell growth after 72 h. Growth inhibition was much stronger in untreated SCC9 cells than in HGF-treated cells (Figure 6a , left side). To investigate whether other epithelial cancer cell lines act in the same way, we analyzed several cell lines, which showed a significant growth inhibition upon gefitinib treatment (Supplementary Figure  S2) . We found kidney-, liver-and tongue-derived cancer cells to become, in the presence of HGF, more independent of EGFR-induced cell proliferation (Figure 6a , right side). 
HGF-induced EGFR interactions are resistant to gefitinib treatment
Given the fact that classical autophosphorylation of the EGFR is not necessary for the binding of the identified EGFR interaction partners, we inquired whether gefitinib, a selective inhibitor of the EGFR TK, influences the inter-receptor cross talk. This is of great importance, because it might implicate a mechanism of primary resistance to EGFR inhibitors. We therefore subjected long-term HGF-treated SCC9 cells for the last 2 hours of the treatment to gefitinib and then stimulated them with AR. In gefitinib-treated cells the level of p-EGFR Y1173 was completely blocked compared with cells solely treated with HGF or untreated cells-confirming the efficiency of gefitinib in blocking EGFR phosphorylation in our model (Figure 6b , upper part). However, the binding capacity of the EGFR interaction partners integrin beta-4, Axl, CDCP1 and EphA2 was unchanged or even higher in the presence of gefitinib (Figure 6b , lower part).
Met TK-inhibition restores gefitinib sensitivity Having found that HGF-induced Met activation very efficiently confers resistance to EGFR TKI treatment in cancer cells, we wondered if a pretreatment with a Met TKI restores gefitinib sensitivity. Therefore, we incubated SCC9 cells with the Met TKI AMG-458 derivate 1 before the cells were treated with gefitinib and HGF. Pretreatment with AMG-458 completely blocked HGFinduced cell scattering ( Figure 6c ) and fully recovered the antiproliferative effects of gefitinib (Figure 6d ).
DISCUSSION
Here we describe novel HGF-induced EGFR functions in human cancer cell lines with a strong implication for understanding the mechanisms of HGF-induced resistance to EGFR TKIs. We are the first to show that HGF impedes phosphorylation of the EGFR and induces two novel cancer-promoting functions. The first function is abolishment of classical EGFR signaling, which makes cancer cells independent of these signaling mechanisms and at the same time neutralizes the point of action for EGFR TK-targeted drugs. The second function, caused by HGF, enables the EGFR to interact with proteins, which are known to be markers of a highly metastatic phenotype. Therefore, our results indicate that, together, these novel EGFR functions can boost tumor progression-independent of EGFR kinase activity. Activation of EGFR has been frequently reported to promote tumor progression. 3 However, expression levels of EGFR in human cancers do not correlate with responsiveness to EGFR TKI treatment 39 and the rate of complete tumor regression is very low. 31 The expression and activation of Met has been implicated in EGFR resistance to TKIs in NSCLC and colon cancer patients. Engelman et al. 24 reported that MET amplification causes gefitinib resistance in lung cancer cell lines by circumventing the blocked EGFR activity via a HER3-dependent activation of the PI3K-Akt pathway. In addition, in vitro studies in EGFR-mutated NSCLC cell lines show that exposure to HGF induces EGFR TKI resistance 31, [44] [45] [46] and inhibition of Met/HGF restores gefitinib sensitivity. 24, 28, 47 We were the first who could show the underlying reason why EGFR-targeted drugs fail to work in EGFR-expressing tumors: HGF simply anticipates the mode of action, as EGFR TK activity, as well as the classical downstream signaling, is no longer required for tumor growth. Considering the fact that EGFR is overexpressed in various tumors of epithelial origin and our current finding that HGF blocks EGFR TK activity, we postulate that blocking HGF/Met before or together with EGFR TKI treatment might be a useful strategy in targeting EGFR-and Met-positive tumors.
Receptor cross talk is an important mechanism during tumor progression. Several RTKs have been shown to transactivate and directly bind to members of other RTK families. Our present study shows that in the presence of HGF, the EGFR directly interacts with several cytoplasmic proteins, as well as with transmembrane proteins like CDCP1, EphA2 and Axl. CDCP1, a 135 kDa glycoprotein, is overexpressed in breast, gastric and lung cancers 48 and was shown to be associated with high invasiveness. Consistent with its role in metastatic spread, silencing of CDCP1 reduced the migratory behavior of lung and gastric cancer cell lines. Therefore, CDCP1 seems to be a potential therapeutic target although its signaling mechanism is still unknown. Besides their well-described tumor-associated functions, the RTKs EphA2 and Axl were both recently shown to confer acquired resistance to anti-HER2 treatment in breast cancer cells. 49, 50 A similar resistance mechanism probably contributes to our observed EGFR TKI resistance. In our present study, we not only found higher expression levels of EphA2 and Axl upon HGF treatment but also a direct interaction with EGFR, indicating a TK-independent role of EGFR in stabilization of these receptors, thereby maybe empowering cancer cells with the ability to receive further tumor-promoting signals from the tumor microenvironment.
In addition to the well-known prosurvival and proproliferative roles of EGFR, which are mediated via activation of the EGFR TK domain and further downstream PI3K, MAPK and STAT signaling cascades, the EGFR seems to function in another dimension of complexity: a kinase-independent stabilization of cancerassociated proteins.
Taken together, we demonstrate here that in the presence of HGF, the EGFR TK becomes inactive, and that this inactive TK leads to primary resistance to EGFR-targeted drugs and at the same time induces interactions of the EGFR with various tumor relevant proteins (as described in Figure 7 ). These novel functions of EGFR may endow tumor cells with an increased survival capacity even in the presence of targeted anticancer therapeutics, including TKIs. Thus, pretreatment with HGF/Met inhibitors before EGFR-targeted therapy, as well as targeting HGF/Met-induced EGFR interactors may both be necessary for elimination of epithelial cancers. presence of 10% fetal calf serum, except for the MEK and PI3K inhibitor treatment of A498 and caki-2 cells, cells were cultured in 1% FCS; and for the migration assay, SCC9 cells were cultured in serum-free-medium/0.1% BSA. Chemical inhibitors, except gefitinib, were added 15 min before HGF treatment and were present during the entire period of the experiment. The inhibitors, dissolved in dimethyl sulfoxide (DMSO), were used in the following concentrations: metalloproteinase inhibitor batimastat BB94 (5 mM) (British Biotech, Oxford, UK), Met inhibitor AMG-458 derivate 1 (4 mM) (Vichem, Budapest, Hungary), 51 MEK inhibitors UO126 (5 mM) and PD98059 (50 mM) (Calbiochem, Darmstadt, Germany), PI3K inhibitor wortmannin (50 nM) (Sigma Deisenhofen, Germany). Gefitinib (2 mM) (LC Laboratories, Woburn, MA, USA) was present during the last 2 h of the 24 h HGF treatment. Control cells were subjected to DMSO only. Cells were treated with HGF 50 ng/ml (R&D Systems, Wiesbaden, Germany) for 24 h, followed by stimulations with either 50 ng or 500 ng/ml AR (R&D Systems), 2 ng/ml EGF (Peprotech, Hamburg, Germany), 5 ng/ml HB-EGF (R&D Systems) or 5 ng/ml TGFa (R&D Systems) for 5 min, and lysed. Protein lysates were subjected to western blot analysis or immunoprecipitation. To verify the biological activity of the released AR, the conditioned medium of 24 h HGF-treated SCC9 was transferred to untreated SCC9 cells for 5 min The neutralizing AR antibody (R&D Systems) was added in a final concentration of 5 mg/ml to the conditioned medium, 1 h before stimulation. Phasecontrast pictures were taken on a Zeiss Axio Observer.A1 microscope (Zeiss, Oberkochen, Germany) ELISA AR release was measured using a sandwich ELISA (R&D Systems). Cells were treated with 50 ng/ml HGF for 24 h. The harvested supernatants were clarified by centrifugation, diluted 1:10 in PBS/1% BSA and assayed according to the manufacturer's instructions.
MATERIALS AND METHODS
Quantitative RT-PCR SCC9 cells were treated with 50 ng/ml HGF for 2 h. Isolated total RNA was transcribed into complementary DNA (cDNA) using AMV Reverse Transcriptase (Roche Diagnostics, Mannheim, Germany). For cDNA quantitation, 32 ng cDNA was mixed with 0.5 mM gene-specific primers (primers were as follows: AR: 5 0 -TGGTGCTGTCGCTCTTGATA-3 0 (forward) and 5 0 -GCCAGGTATTTGTGGTTCGT-3 0 (reverse); reverence gene cyclophilin A: 5 0 -GCCGCGTCTCCTTTGAGCT-3 0 (forward) and 5 0 -CACCACATGCTTGCC ATCC-3 0 (reverse)) and Fast SYBR Green Master Mix (AB Applied Biosystems, Darmstadt, Germany) to a total volume of 15 ml. The PCR was carried out on a StepOnePlus instrument (Applied Biosystems), according to the manufacturer's instructions.
Immunoblotting and immunoprecipitation
For western blot analysis, differentially treated cells were washed with cold PBS, lysed in lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM ethylene diamine tetra-acetic acid, 10% glycerol, 1% Triton X-100, 10 mM Na 4 P 2 O 7 ) containing protease and phosphatase inhibitors for 15 min at 4 1C. Insoluble cell fragments were removed by centrifugation. For immunoprecipitation 2 mg of total protein, 1 mg of homemade monoclonal antibody against human EGFR clone 108.1 (has been characterized before 52 ) together with 10 ml of protein A-sepharose (GE Healthcare, Munich, Germany) were incubated for 4 h at 4 1C. Precipitates were washed three times with HNTG buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 40% glycerol, 0.4% Triton X-100). Cell lysates and immunoprecipitates were diluted in SDS sample buffer, separated on 7.5 or 12.5% SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were incubated with the primary antibodies against p-EGFR Y1173 (Cell Signaling Technologies, Danvers, MA, USA), p-EGFR Y845 (Cell Signaling Technologies), p-EGFR Y1045 (Cell Signaling Technologies), p-Met Y1234/1235 (Cell Signaling Technologies), Met (Santa Cruz Biotechnology, Heidelberg, Germany), p-tyrosine (Upstate Biotechnology, Darmstadt, Germany), p-Erk1/2 (Cell Signaling Technologies), p-Akt (Cell Signaling Technologies), Axl (Santa Cruz Biotechnology), CDCP1 (Cell Signaling Technologies), EphA2 (Upstate), integrin beta-4 (Abcam, Cambridge, UK) and JAK1 (Cell Signaling Technologies). The membranes were stripped and reblotted for EGFR (Cell Signaling Technologies) and tubulin (Sigma) to verify protein loadings. Secondary HRP-conjugated anti-mouse (Sigma), anti-rabbit (Bio-Rad, Munich, Germany), and anti-goat (Jackson ImmunoResearch, Hamburg, Germany) antibodies were used and were detected with an ECL reagent (PerkinElmer, Rodgau, Germany). Densitometric analysis of band intensity was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Flow cytometry
For FACS analyses, cells were treated with 50 ng/ml HGF (R&D Systems) for 24 h or 50 ng/ml EGF (Peprotec) for 10 min to investigate the effects on EGFR internalization. Differentially treated cells were harvested on ice, resuspended in PBS/1% BSA, and incubated with either EGFR extracellular domain-specific mAb (clone 108.1) or the corresponding isotype control at a concentration of 20 mg/ml for 1 h at 4 1C. The cells were washed once followed by 45 min incubation at 4 1C in the dark with the PE-conjugated secondary donkey anti-mouse IgG antibody (Jackson ImmunoResearch). Stained cells were washed twice with PBS/1% BSA, and resuspended in 400 ml PBS/1% BSA. The analyses were performed using a FACScan flow cytometer (BD Biosciences, Heidelberg, Germany) and CellQuest software (BD Biosciences).
Migration assay SCC9 cells were treated with 50 ng/ml HGF for 24 h, and 50 000 cells were seeded on to a membrane with 8-mM pores of a modified boyden chamber (Schubert and Weiss, Munich, Germany) in 500 ml of serum-free medium/ 0.1% BSA. In the lower chamber 700 ml serum-free medium/0.1% BSA alone or containing 2 ng/ml TGFa (R&D Systems) served as chemoattractants. After 4 h, migrated cells were fixed in methanol and stained with crystal violet. Pictures were taken on a Zeiss Observer.A1 microscope (Zeiss). Cell migration was deduced by measuring the membrane area covered with migrated cells using the Photoshop CS3 extended measurement feature.
EGFR co-immunoprecipitation and mass spectrometry 6 cells/dish were seeded) and stimulated for 5 min with 500 ng/ml AR. Lysates were precleared by centrifugation, followed by coimmunoprecipitation of 6 mg of total protein, 8 mg of anti-EGFR antibody (clone 108.1) together with 80 ml of protein A-sepharose for 4 h at 4 1C. Precipitates were washed three times with lysis buffer, boiled for 5 min, and then separated on a 4-12% SDS-PAGE over a separation distance of about 40 mm. The gel was stained with Coomassie blue and each of the two lanes of the gel was cut into four slices. Subsequent tryptic in-gel digests, peptide purification, LC-MS/MS analysis, and database searches were done, as described elsewhere. 53 Data processing was performed using MaxQuant software (version 1.1.1.21). Two biological replicates were analyzed.
Cell proliferation assay
For the SCC9 cell proliferation assays, cells were seeded in 96-well plates at 1000 cells per well in 100 ml cell culture medium containing 10% FCS and cultured for 72 h with various concentrations of gefitinib in the absence or presence of 50 ng/ml HGF. AMG-458 derivate 1 was added 1 h before addition of gefitinib and HGF. Cellular metabolism was assessed using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Briefly, 20 ml of MTT solution (5 mg/ml in PBS) was added to the cells. After 2 h at 37 1C, the formazan crystals formed were solubilized by addition of 50 ml stop solution (10% SDS, 5% butanol and 0.01 M HCl). Absorbance for each well was read at 570 nm using a microplate reader. For the cell line screen, cells were seeded in 100 ml per well in 96-well plates: A498, caki-2, HepG2, SCC9, SCC25 were seeded at 1000 cells per well; Huh7 at 2000 cells per well and SCC4 at 800 cells per well. Cells were treated with 2 mM gefitinib and 50 ng/ml HGF in RPMI 10% FCS medium. Proliferation was measured using CellTiter-Glo Luminescent cell Viability Assay (Promega, Mannheim, Germany), following manufacturer's instructions. Cell growth was calculated as a percentage of the untreated control. Experiments were done thrice and in triplicates.
